Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse — KIRIMID  

First or Second Relapse Clinical Trial

Official title: Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

Status Completed

Clinical Trial Summary

The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• First or Second Relapse
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Patients With Multiple Myeloma Experiencing a

• NCT number: NCT01217203
• Study type: Interventional
• Source: Innate Pharma
• Status: Completed
• Phase: Phase 1
• Start date: September 2010
• Completion date: February 2014